Home
|Insights
|The Long and Winding Road for BIOSIMILARS: Charting a Pathway through Patent, FDA, Antitrust, Prescription Filling, Reimbursement and Liability Law

PDF Link

The Long and Winding Road for BIOSIMILARS: Charting a Pathway through Patent, FDA, Antitrust, Prescription Filling, Reimbursement and Liability Law

Publication | 09.18.15

Contacts

Barbara H. Ryland
Senior Counsel
- Washington, D.C.
  - D | +1.202.624.2970
YnJ5bGFuZEBjcm93ZWxsLmNvbQ==
Deborah H. Yellin
Partner
She/Her/Hers
- Washington, D.C.
  - D | +1.202.624.2947
ZHllbGxpbkBjcm93ZWxsLmNvbQ==

Insights

Publication | 01.09.25

A ‘no-duh’ verdict? The Outcome Of Penn State v. Vintage Brand Allows Brand Owners To Chillax A Bit More

Publication | 12.26.24
Efficiency v Flexibility – The Patent Prosecution Highway (PPH) Program’s Pros and Cons
Publication | 12.23.24
Small Business Administration Proposed Rule Would Enact Material Changes As Well As Promote Regulatory Uniformity Across Size And Status Programs – Part 1
Publication | 12.23.24
The Federal Circuit Defines The “Public Disclosure” Exception To Prior Art Under 35 U.S.C. § 102(b)(2)

View All Insights

Subscribe

to the latest insights from our team